Parimal Misra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11987136/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PIMT/TGS1: An evolving metabolic molecular switch with conserved methyl transferase activity. Drug Discovery Today, 2022, , .	6.4	0
2	Amberlyst-15 catalysed synthesis of novel indole derivatives under ultrasound irradiation: Their evaluation as serotonin 5-HT2C receptor agonists. Bioorganic Chemistry, 2021, 116, 105380.	4.1	4
3	Novel isatin–indole derivatives as potential inhibitors of chorismate mutase (CM): their synthesis along with unexpected formation of 2-indolylmethylamino benzoate ester under Pd–Cu catalysis. RSC Advances, 2020, 10, 289-297.	3.6	6
4	Synthesis of 3-indolylmethyl substituted (pyrazolo/benzo)triazinone derivatives under Pd/Cu-catalysis: Identification of potent inhibitors of chorismate mutase (CM). Bioorganic Chemistry, 2019, 91, 103155.	4.1	11
5	Statins exacerbate glucose intolerance and hyperglycemia in a high sucrose fed rodent model. Scientific Reports, 2019, 9, 8825.	3.3	16
6	ERK1/2 activated PHLPP1 induces skeletal muscle ER stress through the inhibition of a novel substrate AMPK. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1702-1716.	3.8	21
7	2-[2-(4-(trifluoromethyl)phenylamino)thiazol-4-yl]acetic acid (Activator-3) is a potent activator of AMPK. Scientific Reports, 2018, 8, 9599.	3.3	10
8	MicroRNA-712 restrains macrophage pro-inflammatory responses by targeting LRRK2 leading to restoration of insulin stimulated glucose uptake by myoblasts. Molecular Immunology, 2017, 82, 1-9.	2.2	11
9	Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism. Scientific Reports, 2015, 5, 13823.	3.3	49
10	Co-activator binding protein PIMT mediates TNF-α induced insulin resistance in skeletal muscle via the transcriptional down-regulation of MEF2A and GLUT4. Scientific Reports, 2015, 5, 15197.	3.3	25
11	MicroRNA-16 modulates macrophage polarization leading to improved insulin sensitivity in myoblasts. Biochimie, 2015, 119, 16-26.	2.6	24
12	Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis. Biochimie, 2014, 98, 63-74.	2.6	57
13	Peroxisome Proliferator-Activated Receptor-α Signaling in Hepatocarcinogenesis. Sub-Cellular Biochemistry, 2013, 69, 77-99.	2.4	21
14	Ultrasound-based approach to spiro-2,3-dihydroquinazolin-4(1H)-ones: their in vitro evaluation against chorismate mutase. Tetrahedron Letters, 2013, 54, 495-501.	1.4	59
15	Novel alkynyl substituted 3,4-dihydropyrimidin-2(1H)-one derivatives as potential inhibitors of chorismate mutase. Bioorganic Chemistry, 2013, 51, 48-53.	4.1	5
16	The Med1 Subunit of the Mediator Complex Induces Liver Cell Proliferation and Is Phosphorylated by AMP Kinase. Journal of Biological Chemistry, 2013, 288, 27898-27911.	3.4	19
17	ERK2-Mediated Phosphorylation of Transcriptional Coactivator Binding Protein PIMT/NCoA6IP at Ser298 Augments Hepatic Gluconeogenesis. PLoS ONE, 2013, 8, e83787.	2.5	32
18	AlCl3 mediated unexpected migration of sulfonyl groups: regioselective synthesis of 7-sulfonyl indoles of potential pharmacological interest. Chemical Communications. 2012. 48. 10434.	4.1	47

PARIMAL MISRA

#	Article	IF	CITATIONS
19	C–N bond formation under Cu-catalysis: Synthesis and in vitro evaluation of N-aryl substituted thieno[2,3-d]pyrimidin-4(3H)-ones against chorismate mutase. Bioorganic and Medicinal Chemistry, 2012, 20, 5127-5138.	3.0	11
20	AlCl3 induced (hetero)arylation of 2,3-dichloroquinoxaline: A one-pot synthesis of mono/disubstituted quinoxalines as potential antitubercular agents. Bioorganic and Medicinal Chemistry, 2012, 20, 1711-1722.	3.0	35
21	Cu-mediated N-arylation of 1,2,3-triazin-4-ones: Synthesis of fused triazinone derivatives as potential inhibitors of chorismate mutase. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1146-1150.	2.2	45
22	A new route to indoles via in situ desilylation–Sonogashira strategy: identification of novel small molecules as potential anti-tuberculosis agents. MedChemComm, 2011, 2, 1006.	3.4	44
23	A Pd-mediated new strategy to functionalized 2-aminochromenes: Their in vitro evaluation as potential anti tuberculosis agents. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6433-6439.	2.2	33
24	Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore. European Journal of Medicinal Chemistry, 2005, 40, 977-990.	5.5	41
25	Conformationally Restricted 3,4-Diarylfuranones (2,3a,4,5-Tetrahydronaphthofuranones) as Selective Cyclooxygenase-2 Inhibitors ChemInform, 2003, 34, no.	0.0	0
26	Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1639-1643.	2.2	48
27	DRF 2655: A Unique Molecule that Reduces Body Weight and Ameliorates Metabolic Abnormalities. Obesity, 2003, 11, 292-303.	4.0	12
28	Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. British Journal of Pharmacology, 2003, 140, 527-537.	5.4	77
29	PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor Î ³ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 763-771.	2.5	62
30	Interaction of PIMT with Transcriptional Coactivators CBP, p300, and PBP Differential Role in Transcriptional Regulation. Journal of Biological Chemistry, 2002, 277, 20011-20019.	3.4	83
31	Phosphorylation of Transcriptional Coactivator Peroxisome Proliferator-activated Receptor (PPAR)-binding Protein (PBP). Journal of Biological Chemistry, 2002, 277, 48745-48754.	3.4	67
32	Defects of the Heart, Eye, and Megakaryocytes in Peroxisome Proliferator Activator Receptor-binding Protein (PBP) Null Embryos Implicate GATA Family of Transcription Factors. Journal of Biological Chemistry, 2002, 277, 3585-3592.	3.4	116
33	(â~')3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(â~')DRF 2725]:Â A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity. Journal of Medicinal Chemistry, 2001, 44, 2675-2678.	6.4	139
34	Euglycemic and hypolipidemic activity of PAT5A: A unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metabolism: Clinical and Experimental, 2000, 49, 1417-1423.	3.4	21